Payment overview · 2025
General Payments
$1,660.23
123 reported records · 22 companies
Healthcare provider profile · identity verified
K Keith Varden, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1417903113
Verified facts
What the public records show
CMS Open Payments records show K Keith Varden, M.D. received $1,660.23 in general payments during 2025 across 123 reported records.
Novo Nordisk Inc accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Linzess, Ozempic, Prolia, Rybelsus, Synthroid, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 329 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 419 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $303.20 | 18.3% | 24 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $222.36 | 13.4% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $219.84 | 13.2% | 28 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $208.30 | 12.6% | 24 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $94.73 | 5.7% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $81.32 | 4.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.88 | 3.7% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $55.08 | 3.3% | 3 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $54.34 | 3.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.73 | 2.9% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.03 | 2.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.26 | 2.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.91 | 1.9% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.46 | 1.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.94 | 1.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.52 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.95 | 1.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.54 | 1.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.04 | 1.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.67 | 1.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.43 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.70 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,660.23 | 123 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $271.78 | 20 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $222.36 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $213.89 | 15 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $151.72 | 12 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $108.77 | 16 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $81.32 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $61.24 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.58 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.58 | 12 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $55.08 | 3 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $54.34 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $51.73 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.83 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $47.34 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.03 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $46.12 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $44.26 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $38.52 | 2 | 2025 |
Source payment records
|
|||||
| BENEFIX Normalized: benefix |
Biological | PFIZER INC. | $38.12 | 1 | 2025 |
Source payment records
|
|||||
| HYMPAVZI Normalized: hympavzi |
Drug | PFIZER INC. | $38.12 | 1 | 2025 |
Source payment records
|
|||||
| XYNTHA Normalized: xyntha |
Biological | PFIZER INC. | $38.12 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $35.70 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $34.94 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $28.12 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $27.46 | 1 | 2025 |
Source payment records
|
|||||
| Clinical Trial Product Normalized: clinical trial product |
Device | Boston Scientific Corporation | $25.94 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.28 | 3 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $11.31 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $5.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 185 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 144 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 95 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 329 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 48 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 127 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 72 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
95 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
127 | 31 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
161 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
185 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
144 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
113 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
329 | 62 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
419 | 83 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1681 | 387 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1411 | 365 |
| Amlodipine Besylate | Amlodipine Besylate | 1154 | 318 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1124 | 306 |
| Omeprazole | Omeprazole | 1014 | 273 |
| Losartan Potassium | Losartan Potassium | 880 | 243 |
| Trazodone Hcl | Trazodone Hcl | 744 | 209 |
| Gabapentin | Gabapentin | 742 | 199 |
| Metoprolol Succinate | Metoprolol Succinate | 656 | 177 |
| Furosemide | Furosemide | 653 | 191 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 653 | 181 |
| Tamsulosin Hcl | Tamsulosin Hcl | 608 | 163 |
| Metformin Hcl Er | Metformin Hcl | 592 | 175 |
| Celecoxib | Celecoxib | 536 | 175 |
| Sertraline Hcl | Sertraline Hcl | 505 | 120 |
| Simvastatin | Simvastatin | 475 | 121 |
| Tramadol Hcl | Tramadol Hcl | 466 | 115 |
| Montelukast Sodium | Montelukast Sodium | 462 | 135 |
| Meloxicam | Meloxicam | 439 | 131 |
| Hydrochlorothiazide | Hydrochlorothiazide | 421 | 124 |
| Buspirone Hcl | Buspirone Hcl | 420 | 103 |
| Eliquis | Apixaban | 419 | 83 |
| Tizanidine Hcl | Tizanidine Hcl | 414 | 127 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 401 | 123 |
| Potassium Chloride | Potassium Chloride | 392 | 101 |
| Pravastatin Sodium | Pravastatin Sodium | 389 | 96 |
| Lisinopril | Lisinopril | 386 | 105 |
| Glimepiride | Glimepiride | 378 | 110 |
| Carvedilol | Carvedilol | 365 | 87 |
| Metformin Hcl | Metformin Hcl | 356 | 89 |
| Allopurinol | Allopurinol | 341 | 97 |
| Escitalopram Oxalate | Escitalopram Oxalate | 331 | 97 |
| Mirtazapine | Mirtazapine | 330 | 87 |
| Ozempic | Semaglutide | 329 | 62 |
| Alprazolam | Alprazolam | 326 | 67 |
| Ezetimibe | Ezetimibe | 318 | 93 |
| Duloxetine Hcl | Duloxetine Hcl | 309 | 81 |
| Bupropion Xl | Bupropion Hcl | 308 | 93 |
| Clopidogrel | Clopidogrel Bisulfate | 293 | 72 |
| Donepezil Hcl | Donepezil Hcl | 287 | 68 |
| Citalopram Hbr | Citalopram Hydrobromide | 284 | 75 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 267 | 71 |
| Famotidine | Famotidine | 229 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 226 | 84 |
| Clonazepam | Clonazepam | 214 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 213 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 73 |
| Fluoxetine Hcl | Fluoxetine Hcl | 207 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 205 | 37 |
| Memantine Hcl | Memantine Hcl | 198 | 39 |
| Farxiga | Dapagliflozin Propanediol | 185 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 184 | 50 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 173 | 48 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 164 | 43 |
| Azithromycin | Azithromycin | 162 | 136 |
| Pregabalin | Pregabalin | 162 | 39 |
| Myrbetriq | Mirabegron | 161 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 150 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 146 | 48 |
| Jardiance | Empagliflozin | 144 | 30 |
| Prednisone | Prednisone | 136 | 75 |
| Diclofenac Sodium | Diclofenac Sodium | 131 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 128 | 39 |
| Spironolactone | Spironolactone | 127 | 29 |
| Synthroid | Levothyroxine Sodium | 127 | 31 |
| Atenolol | Atenolol | 126 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 118 | 67 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 117 | 70 |
| Methylprednisolone | Methylprednisolone | 115 | 103 |
| Mounjaro | Tirzepatide | 113 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 113 | 40 |
| Ropinirole Hcl | Ropinirole Hcl | 113 | 23 |
| Cephalexin | Cephalexin | 110 | 75 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 110 | 26 |
| Azelastine Hcl | Azelastine Hcl | 106 | 48 |
| Telmisartan | Telmisartan | 102 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 101 | 26 |
| Lorazepam | Lorazepam | 100 | 22 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 100 | 35 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 98 | 76 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 95 | 25 |
| Linzess | Linaclotide | 95 | 29 |
| Meclizine Hcl | Meclizine Hcl | 93 | 47 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 90 | 25 |
| Breo Ellipta | Fluticasone/Vilanterol | 89 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 89 | 27 |
| Propranolol Hcl | Propranolol Hcl | 87 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 85 | 26 |
| Olanzapine | Olanzapine | 82 | 12 |
| Valacyclovir | Valacyclovir Hcl | 82 | 29 |
| Tradjenta | Linagliptin | 81 | 11 |
| Fluconazole | Fluconazole | 80 | 54 |
| Temazepam | Temazepam | 80 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 32 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 78 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 76 | 16 |
| Trulicity | Dulaglutide | 74 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 73 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 17 |
| Xarelto | Rivaroxaban | 72 | 20 |
| Alendronate Sodium | Alendronate Sodium | 71 | 16 |
| Finasteride | Finasteride | 70 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 19 |
| Doxepin Hcl | Doxepin Hcl | 67 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 18 |
| Sucralfate | Sucralfate | 66 | 27 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 66 | 17 |
| Diazepam | Diazepam | 63 | 14 |
| Fenofibrate | Fenofibrate | 63 | 16 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 62 | 43 |
| Januvia | Sitagliptin Phosphate | 62 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 62 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 61 | 16 |
| Clonidine Hcl | Clonidine Hcl | 60 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 14 |
| Estradiol | Estradiol | 59 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 23 |
| Midodrine Hcl | Midodrine Hcl | 56 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 56 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 53 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 52 | suppressed |
| Primidone | Primidone | 51 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 49 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 48 | 17 |
| Rybelsus | Semaglutide | 48 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Nystatin | Nystatin | 47 | 33 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 21 |
| Lansoprazole | Lansoprazole | 46 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | 13 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 45 | 23 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 44 | 24 |
| Nitroglycerin | Nitroglycerin | 44 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 18 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 13 |
| Latanoprost | Latanoprost | 42 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | 12 |
| Colchicine | Colchicine | 41 | 18 |
| Rizatriptan | Rizatriptan Benzoate | 41 | 13 |
| Valsartan | Valsartan | 41 | 12 |
| Glipizide | Glipizide | 40 | suppressed |
| Lovastatin | Lovastatin | 40 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | 14 |
| Naproxen | Naproxen | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 38 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Glipizide Er | Glipizide | 37 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 27 |
| Lubiprostone | Lubiprostone | 36 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 35 | suppressed |
| Torsemide | Torsemide | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Ketoconazole | Ketoconazole | 34 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 19 |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 31 | 29 |
| Mupirocin | Mupirocin | 31 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 31 | 13 |
| Cholestyramine | Cholestyramine (With Sugar) | 30 | 15 |
| Lidocaine | Lidocaine | 30 | 11 |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | 12 |
| Gemtesa | Vibegron | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | 12 |
| Baclofen | Baclofen | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | 14 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | 12 |
| Metronidazole | Metronidazole | 26 | 22 |
| Acyclovir | Acyclovir | 25 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 19 |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | 11 |
| Ramipril | Ramipril | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 25 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 16 |
| Topiramate | Topiramate | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Acarbose | Acarbose | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Nystop | Nystatin | 18 | 15 |
| Scopolamine | Scopolamine | 18 | 12 |
| Vancomycin Hcl | Vancomycin Hcl | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Zaleplon | Zaleplon | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Cholestyramine Light | Cholestyramine | 16 | suppressed |
| Ciclopirox | Ciclopirox | 16 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Trandolapril | Trandolapril | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Mesalamine Er | Mesalamine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 12 | 12 |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,660.23 · 123 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BENEFIX, COMIRNATY, CREON, Clinical Trial Product, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, Fluad, Flucelvax, GEMTESA, HYMPAVZI, IBSRELA, JARDIANCE, Kerendia, LEQVIO, LINZESS, MENQUADFI, OTEZLA, Ozempic, PREVNAR 20, PROLIA, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XYNTHA, YUPELRI | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error